The capital band increase strongly suggests Addex will conduct an equity offering imminently to extend its cash runway. Traders should watch for a prospectus or F-3 filing; any offering likely to be highly dilutive given the $10M market cap and minimal cash.
Price Chart
Executive Summary
Addex Therapeutics reported that shareholders approved all resolutions at the 2026 AGM, including amendments to increase the capital band and conditional share capital, enabling potential future equity dilution. The filing is procedural but significant given the company's precarious cash position (CHF 1.6M as of FY2025, with going-concern emphasis from the prior 20-F), signaling a near-term capital raise.
Key Facts
- Shareholders approved all board proposals at the 2026 AGM with 29.35% of outstanding capital represented.
- Amendments to Articles of Association increasing the capital band and conditional share capital were approved, authorizing future equity issuance.
- Auditor BDO SA re-elected; all directors re-elected including Chairman Vincent Lawton, CEO Tim Dyer, and others.
- The prior 20-F (filed May 15, 2026) reported CHF 6.8M net loss, CHF 0.03M revenue, cash of CHF 1.6M (runway through mid-June 2026), and a going-concern qualification.
Financial Impact
Approval of capital band increase and conditional share capital sets the stage for a dilutive equity offering; no specific amount disclosed but company cash runway was only through mid-June 2026, indicating urgent need for funds.
Risk Factors
- Dilution from upcoming equity offering could pressure stock price.
- Going-concern risk persists if financing is delayed or insufficient.
- No disclosed catalyst for pipeline (dipraglurant, GABAB PAM) in this filing; stock relies on binary clinical events.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004375 |
| Exhibit: exh_991.htm | 0001171843-26-004375 |
| Document: 0001171843-26-004375-index-headers.html | 0001171843-26-004375 |
| Document: 0001171843-26-004375-index.html | 0001171843-26-004375 |
| Document: 0001171843-26-004375.txt | 0001171843-26-004375 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.18 | awaiting T+60 | — | $2.90 (−8.81%) |
Oct 2, 2026 24d ago | 6-K | $3.07 | awaiting T+60 | — | $2.90 (−5.54%) |
Sep 28, 2026 28d ago | 6-K | $2.81 | awaiting T+60 | — | $2.90 (−3.20%) |
Sep 25, 2026 4w ago | 6-K | $3.65 | awaiting T+60 | — | $2.90 (−20.55%) |
Aug 26, 2026 8w ago | 6-K | $4.23 | awaiting T+60 | — | $2.90 (+31.44%) |
Jul 8, 2026 15w ago | 6-K | $5.89 $2.98 | ▼ −49.41% | ▼ −51.90% | $2.90 (−50.76%) |
Jun 30, 2026 16w ago | 6-K | $5.70 $3.45 | ▲ +39.47% | ▲ +42.29% | $2.90 (+49.12%) |
Jun 25, 2026 17w ago | 6-K | $5.94 $3.40 | ▲ +42.76% | ▲ +46.49% | $2.90 (+51.18%) |
May 15, 2026 23w ago | 20-F | $6.83 $5.95 | ▲ +12.88% | ▲ +17.74% | $2.90 (+57.54%) |
Apr 23, 2026 26w ago | 6-K | $6.14 $5.60 | ▼ −8.79% | ▼ −13.81% | $2.90 (−52.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers